Wire · opportunities
Revance and Teoxane Announce the FDA Approval of RHA Redensity® Eye for Undereye Hollowing
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 August 2026 · Fusion42 review
The FDA approved RHA Redensity Eye, a hyaluronic acid filler specifically designed for treating moderate to severe under-eye hollowing, with results lasting up to 12 months. This approval is backed by a 52-week U.S. clinical study showing high safety and efficacy, and it is the first filler to demonstrate effectiveness using patient-reported outcomes as a co-primary endpoint in this region.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
Aesthetic med founders focused on dermal fillers must update their pipelines as a new FDA-approved product sets higher safety and patient satisfaction standards for under-eye treatments. This approval opens the door for differentiated products in delicate facial areas that could gain quicker adoption and patient trust.
◆ Coverage
1 source · 20 Aug 2026
◆ Related on Wire
◆ Topics